Article Sidebar

Submitted
November 13, 2024
Accepted
November 13, 2024
Published
November 13, 2024
Download
PDF
Statistic
Read Counter : 527 Download : 336

Main Article Content

Abstract

Background: Chronic kidney disease (CKD) is a global public health issue characterized by a
gradual loss of kidney function over time, poor outcomes, and substantial healthcare costs.
Aim of the Study: The aim of this study was to examine the prevalence of hepatitis C virus
(HCV) infection in patients receiving hemodialysis (HD) and to determine if there is a link
between HCV infection and interleukin-6 levels.
Materials and Methods: A cross-sectional study was conducted from April 1st to
September 20th , 2024. The study involved 200 patients with chronic renal disease undergoing
hemodialysis, aged 20-75 years, who were admitted to Al-Hussein Teaching Hospital in Dhi Qar.
Additionally, 50 healthy control individuals aged 18-50 years, who visited the Main Blood Bank
for blood donation and had no apparent disease, were included. Blood samples (5 ml) were
collected via vein puncture from each participant for serological testing to detect HCV-specific
antibodies, IL-6 levels using ELISA, and HCV viral load determination by PCR.
Results: Our results indicated that 18% of HD patients were infected with HCV. Among the
HD patients, 83.33% of those who tested positive for HCV antibodies by ELISA were confirmed
to HCV-positive by PCR. None of the ELISA-negative HD patients or individuals in the control
group tested positive by PCR. The highest rate of HCV infection (44.44%) among patients had a
viral load between 9,000 and 11,000 IU/mL. The study also demonstrated that HD patients with
HCV infection had the highest mean levels of IL-6 compared to HD patients without HCV
infection.

Keywords

Chronic kidney disease kidney failure Hemodialysis Hepatitis C virus infection IL-6

Article Details

License

Copyright (c) 2024 University of Thi-Qar Journal Of Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Tonelli, M. and Riella, M. 2014. Chronic kidney disease and the aging population. Brazilian
  2. Journal of Nephrology, 36: 1-5.
  3. Afolabi, M.O., Abioye-Kuteyi, A.E., Arogundade, F.A. and Bello, I.S., 2009. Prevalence of
  4. chronic kidney disease in a Nigerian family practice population. South African Family
  5. Practice, 51: 132-137.
  6. Dussol B, Bertheze`ne P, Brunet P, Roubicek C, Berland Y. 1995. Hepatitis C virus infection
  7. among chronic dialysis patients in the south of France: A collaborative study. Am J Kidney Dis
  8. :399– 404.
  9. Noiri E, Nakao A, Oya A, Fujita T, Kimura S. 2001. Hepatitis C virus in blood and dialysate in
  10. hemodialysis. Am J Kidney Dis 37:38–42.
  11. Prati, D. 2006. Transmission of hepatitis C virus by blood transfusions and other medical
  12. procedures: a global review. Journal of hepatology, 45(4), 607-616.
  13. Salama G, Rostaing L, Sandres K, Izopet J. 2000. Hepatitis C virus infection in French
  14. hemodialysis units: A multicenter study. J Med Virol 61:44–51.
  15. Olut, A. I., Ozsakarya, F., and Dilek, M. 2005. Seroprevalence of hepatitis C virus infection and
  16. evaluation of serum aminotransferase levels among haemodialysis patients in Izmir, Turkey.
  17. Journal of international medical research, 33(6), 641-646.
  18. Ibrahim, R. M. and Hashem, B. J. 2019. Seroconversion of hepatitis B and hepatitis C among
  19. hemodialysis patients, Baghdad, 2015. Journal of Health Science, 7: 23-28.
  20. Othman, R. A. and Abbas, Y. A. 2020. Prevalence of Hepatitis B and C in Thi-Qar Province
  21. Iraq from 2015-2019. European Journal of Molecular and Clinical Medicine, 7: 43-48.
  22. Ashkani-Esfahani, S., Alavian, S. M. and Salehi-Marzijarani, M., 2017. Prevalence of hepatitis C
  23. virus infection among hemodialysis patients in the Middle-East: A systematic review and meta
  24. analysis. World journal of gastroenterology, 23: 151-166.
  25. Sidharthan, S., Kohli, A., Sims, Z., Nelson, A., Osinusi, A., Masur, H. and Kottilil, S. 2015.
  26. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clinical Infectious
  27. Diseases, 60: 1743-1751.
  28. Wlassow, M., Poiteau, L., Roudot-Thoraval, F., Rosa, I., Soulier, A., Hézode, C., Ortonne, V.,
  29. Pawlotsky, J. M. and Chevaliez, S. 2019. The new Xpert HCV viral load real-time PCR assay
  30. accurately quantifies hepatitis C virus RNA in serum and whole-blood specimens. Journal of
  31. Clinical Virology, 117: 80-84.
  32. Lee, M. H., Yang, H. I., Yuan, Y., L’Italien, G. and Chen, C. J. 2014. Epidemiology and natural
  33. history of hepatitis C virus infection. World journal of gastroenterology, 20: 9270-9280.
  34. Al-Qahtani, A. A., Alabsi, E. S., AbuOdeh, R., Thalib, L., El Zowalaty, M. E., and Nasrallah, G.
  35. K. 2016. Prevalence of anelloviruses (TTV, TTMDV, and TTMV) in healthy blood donors and
  36. in patients infected with HBV or HCV in Qatar. Virology journal, 13: 1-6.
  37. Amen, N., Maria, M., Azam, M., Aziz, A., Qamar, R., and Bostan, N. J. T. B. 2018. Low
  38. Seroprevalence of torque teno virus in hcv positive patients and phylogenetic analysis from
  39. Pakistani isolates. Trop Biomed, 35: 205-20.
  40. Sghaier, I., Mouelhi, L., Rabia, N. A., Alsaleh, B. R., Ghazoueni, E., Almawi, W. Y. and
  41. Loueslati, B. Y. 2017. Genetic variants in IL-6 and IL-10 genes and susceptibility to
  42. hepatocellular carcinoma in HCV infected patients. Cytokine, 89: 62-67.
  43. Salgüero, S., Medrano, L. M., González-García, J., Berenguer, J., Montes, M. L., Diéz, C.,
  44. Garcia-Broncano, P., Llop-Herrera, E., Pérez-Latorre, L., Bellóno, J. M., Jiménez-Sousa, M. Á.
  45. and Resino, S. 2020. Plasma IP-10 and IL-6 are linked to Child-Pugh B cirrhosis in patients with
  46. advanced HCV-related cirrhosis: a cross-sectional study. Scientific Reports, 10: 1-10.
  47. Guzmán-Fulgencio, M., Jiménez, J. L., Berenguer, J., Fernández-Rodríguez, A., López, J. C.,
  48. Cosín, J., Miralles, P., Micheloud, D., Muñoz-Fernández, M. Á. and Resino, S. 2012. Plasma IL
  49. and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected
  50. patients. Journal of antimicrobial chemotherapy, 67: 1238-1245.
  51. Mourtzikou, A., Alepaki, M., Stamouli, M., Pouliakis, A., Skliris, A. and Karakitsos, P., 2014.
  52. Evaluation of serum levels of IL-6, TNF-α, IL-10, IL-2 and IL-4 in patients with chronic
  53. hepatitis. Inmunología, 33: 41-50.
  54. Tarragô, A. M., da Costa, A. G., Pimentel, J. P., Gomes, S. T., Freitas, F. B., Lalwani, P., de
  55. Araújo, A. R., Victória, F., Victória, M. B., Vallinoto, A. C., Sadahiro, A., Teixeira-Carvalho,
  56. A., Martins-Filho, O. A. and Malheiro, A. 2014. Combined impact of hepatitis C virus genotype
  57. and interleukin-6 and tumor necrosis factor-α polymorphisms on serum levels of pro
  58. inflammatory cytokines in Brazilian HCV-infected patients. Human Immunology, 75: 1075

Similar Articles

You may also start an advanced similarity search for this article.